Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEPHROS INCNEPH · Entity 7279 | CEO Specialty Renal Products | May 24, 2021 | June 01, 2021 |
| Rezolute, Inc.RZLT · Entity 1990 | CFO | July 02, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEPHROS INC
Report date May 24, 2021 · Filed June 01, 2021 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy UTMA #1 | 8,947 |
Reported balance
After 2021-05-27 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2021-05-27 · Tax withholding · Disposed 349 · Balance 8,947 |
| Common StockSEC Table I · non-derivative | IndirectBy UTMA #2 | 8,669 |
Reported balance
After 2021-05-27 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2021-05-27 · Tax withholding · Disposed 349 · Balance 8,669 |
Rezolute, Inc.
Report date July 02, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 411,400 |
Reported balance
After 2026-07-02 transaction · row 1
1 source rowRow 1 · 2026-07-02 · Tax withholding · Disposed 3,062 · Balance 411,400 F1: The disposition reported on this Form 4 represents shares disposed of by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The disposition is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
| Common SharesSEC Table I · non-derivative | IndirectHeld by minor child #2 | 7,000 |
Reported balance
Holding disclosure · report date 2026-07-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 7,000 |
| Common SharesSEC Table I · non-derivative | IndirectHeld by minor child #3 | 7,000 |
Reported balance
Holding disclosure · report date 2026-07-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7,000 |
| Common SharesSEC Table I · non-derivative | IndirectHeld by PoC Capital LLC | 40,000 |
Reported balance
Holding disclosure · report date 2026-07-02 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 40,000 F2: PoC Capital, LLC is a California limited liability company managed by the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| Common SharesSEC Table I · non-derivative | IndirectHeld by spouse | 20,000 |
Reported balance
Holding disclosure · report date 2026-07-02 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 20,000 |
| Common SharesSEC Table I · non-derivative | IndirectHeld by minor child #1 | 23,000 |
Reported balance
Holding disclosure · report date 2026-07-02 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 23,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The disposition reported on this Form 4 represents shares disposed of by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The disposition is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2: PoC Capital, LLC is a California limited liability company managed by the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2018 Filed May 14, 2018 11:27 UTC | NEPHROS INC NEPH · Entity 7279 | OtherCommon Stock | 40,000 | $0.30 | $12,000.00 |
DisclosureSEC source: 0000914190-18-000195 · edgar.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By PoC Capital, LLC Disclosed balance after: 95,000 F2 · ownership.nature: The Reporting Person is a managing director of the LLC that owns the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 10, 2018 Filed Apr 12, 2018 20:12 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 12,000 | $0.45 | $5,400.00 |
DisclosureSEC source: 0000914190-18-000139 · edgar.xml · nonDerivative · entry 4 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #2 Disclosed balance after: 63,166 Read SEC document |
| April 10, 2018 Filed Apr 12, 2018 20:12 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 12,000 | $0.45 | $5,400.00 |
DisclosureSEC source: 0000914190-18-000139 · edgar.xml · nonDerivative · entry 3 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #1 Disclosed balance after: 65,666 Read SEC document |
| April 10, 2018 Filed Apr 12, 2018 20:12 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 55,000 | $0.45 | $24,750.00 |
DisclosureSEC source: 0000914190-18-000139 · edgar.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By PoC Capital, LLC Disclosed balance after: 55,000 F2 · ownership.nature: The Reporting Person is a managing director of the LLC that owns the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 01, 2018 Filed Feb 22, 2018 21:05 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 218,419 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0000914190-18-000057 · edgar.xml · derivative · entry 5 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 982,887 Underlying: Common Stock · 218,419 shares Expires 2025-04-15 F3 · derivative.exercise_date: On 4/15/2015, the Reporting Person was granted an option to purchase up to 2,184,193 shares of common stock of the Company. 35% of the shares subject to the option (relating to a total of 764,468 shares) vest quarterly in 16 equal amounts, commencing on 6/30/2015. 15% of the shares subject to the option will vest, if ever, upon the listing of the Company's common stock on NASDAQ, NYSE, or such other exchange as the Board may later determine. The remaining 50% of the shares subject to the option will vest, if ever, upon the Company's achievement of certain annual revenue milestones as specified in that certain Employment Agreement dated 4/15/2015 between the Reporting Person and the Company. The Company achieved the $3,000,000 annual revenue milestone in fiscal year 2017 and 218,419 options vested on 2/1/18. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 16:29 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 837,125 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000914190-17-000387 · edgar.xml · derivative · entry 6 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 837,125 Underlying: Common Stock · 837,125 shares Expires 2027-12-20 F4 · derivative.exercise_date: On 12/20/17, the Reporting Person was granted an option to purchase 837,125 shares of common stock of the Company. 25% of the shares subject to the option (relating to a total of 209,282 shares) vest on 12/20/18 and the remaining 75% of the shares subject to the option (relating to a total of 627,843 shares) vest quarterly in 12 equal amounts, commencing on 3/20/19. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 16:29 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 180,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-17-000387 · edgar.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 892,958 F1 · shares: On December 20, 2017, the Company granted 180,000 shares of restricted stock (the "Restricted Stock") to the Reporting Person in lieu of a cash bonus. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan. The Restricted Stock vests six months following the grant date. Read SEC document |
| September 06, 2017 Filed Sep 6, 2017 21:13 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 28,000 | $0.24 | $6,818.00 |
DisclosureSEC source: 0000914190-17-000277 · edgar.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 712,958 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.23 to $0.25 inclusive. The reporting person undertakes to provide Nephros, Inc., any security holder of Nephros, Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F1 · balance_after: Includes 17,756 shares of restricted stock that vest on September 30, 2017. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 21:13 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 1,580 | $0.24 | $371.30 |
DisclosureSEC source: 0000914190-17-000277 · edgar.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 684,958 F1 · balance_after: Includes 17,756 shares of restricted stock that vest on September 30, 2017. Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 16:51 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 2,000 | $0.25 | $500.00 |
DisclosureSEC source: 0000914190-17-000259 · edgar.xml · nonDerivative · entry 3 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #2 Disclosed balance after: 51,166 Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 16:51 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 2,000 | $0.25 | $500.00 |
DisclosureSEC source: 0000914190-17-000259 · edgar.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #1 Disclosed balance after: 53,666 Read SEC document |
| August 11, 2017 Filed Aug 11, 2017 21:35 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 70,000 | $0.26 | $18,200.00 |
DisclosureSEC source: 0000914190-17-000236 · edgar.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 683,378 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.2545 to $0.2771 inclusive. The reporting person undertakes to provide Nephros, Inc., any security holder of Nephros, Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 9,165 shares of restricted stock that vest on June 14, 2017, 213,068 shares of restricted stock that vest on June 23, 2017 and 17,756 shares of restricted stock that vest on September 30, 2017. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 20:19 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 3,961 | $0.26 | $1,029.86 |
DisclosureSEC source: 0000914190-17-000167 · edgar.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613,378 F1 · balance_after: Includes 9,165 shares of restricted stock that vest on June 14, 2017, 213,068 shares of restricted stock that vest on June 23, 2017 and 17,756 shares of restricted stock that vest on September 30, 2017. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 20:19 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 7,500 | $0.26 | $1,950.00 |
DisclosureSEC source: 0000914190-17-000167 · edgar.xml · nonDerivative · entry 3 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #2 Disclosed balance after: 49,166 Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 20:19 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 10,000 | $0.26 | $2,600.00 |
DisclosureSEC source: 0000914190-17-000167 · edgar.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #1 Disclosed balance after: 51,666 Read SEC document |
| May 19, 2017 Filed May 19, 2017 21:55 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 7,500 | $0.26 | $1,912.50 |
DisclosureSEC source: 0000914190-17-000160 · edgar.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 609,417 F1 · balance_after: Includes 9,165 shares of restricted stock that vest on June 14, 2017, 213,068 shares of restricted stock that vest on June 23, 2017 and 17,756 shares of restricted stock that vest on September 30, 2017. Read SEC document |
| May 18, 2017 Filed May 19, 2017 21:55 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 22,500 | $0.26 | $5,737.50 |
DisclosureSEC source: 0000914190-17-000160 · edgar.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,917 F1 · balance_after: Includes 9,165 shares of restricted stock that vest on June 14, 2017, 213,068 shares of restricted stock that vest on June 23, 2017 and 17,756 shares of restricted stock that vest on September 30, 2017. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 20:49 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 17,756 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-17-000117 · edgar.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 579,417 F1 · shares: On March 31, 2017, the Company granted 17,756 shares of restricted stock (the "Restricted Stock") to the Reporting Person in satisfaction of previously-deferred base salary. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan. The Restricted Stock vests six months following the grant date. F2 · balance_after: Includes 9,165 shares of restricted stock that vest on June 14, 2017, 213,068 shares of restricted stock that vest on June 23, 2017 and 17,756 shares of restricted stock that vest on September 30, 2017. Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 21:52 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock Warrants (Right to Buy) · Derivative | 41,666 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0000914190-17-000112 · edgar.xml · derivative · entry 10 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #2 Disclosed balance after: 41,666 Underlying: Common Stock · 41,666 shares Expires 2022-03-17 F2 · price: The reported securities have a purchase price of $0.30 per share of Common Stock. In addition, the reporting person indirectly received a Warrant to purchase a number of shares of Common Stock equal to 100% of the number of shares of Common Stock otherwise purchased. The reporting person indirectly purchased 41,666 shares of Common Stock and was indirectly issued a related Warrant to acquire up to 41,666 shares of Common Stock. Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 21:52 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock Warrants (Right to Buy) · Derivative | 41,666 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0000914190-17-000112 · edgar.xml · derivative · entry 9 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #1 Disclosed balance after: 41,666 Underlying: Common Stock · 41,666 shares Expires 2022-03-17 F2 · price: The reported securities have a purchase price of $0.30 per share of Common Stock. In addition, the reporting person indirectly received a Warrant to purchase a number of shares of Common Stock equal to 100% of the number of shares of Common Stock otherwise purchased. The reporting person indirectly purchased 41,666 shares of Common Stock and was indirectly issued a related Warrant to acquire up to 41,666 shares of Common Stock. Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 21:52 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 41,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000914190-17-000112 · edgar.xml · nonDerivative · entry 3 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #2 Disclosed balance after: 41,666 F2 · price: The reported securities have a purchase price of $0.30 per share of Common Stock. In addition, the reporting person indirectly received a Warrant to purchase a number of shares of Common Stock equal to 100% of the number of shares of Common Stock otherwise purchased. The reporting person indirectly purchased 41,666 shares of Common Stock and was indirectly issued a related Warrant to acquire up to 41,666 shares of Common Stock. Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 21:52 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 41,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000914190-17-000112 · edgar.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA #1 Disclosed balance after: 41,666 F2 · price: The reported securities have a purchase price of $0.30 per share of Common Stock. In addition, the reporting person indirectly received a Warrant to purchase a number of shares of Common Stock equal to 100% of the number of shares of Common Stock otherwise purchased. The reporting person indirectly purchased 41,666 shares of Common Stock and was indirectly issued a related Warrant to acquire up to 41,666 shares of Common Stock. Read SEC document |
| December 23, 2016 Filed Dec 23, 2016 21:44 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 213,068 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-16-000993 · edgar.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,661 F1 · shares: On December 23, 2016, the Company granted 213,068 shares of restricted stock (the "Restricted Stock") to the Reporting Person in lieu of a $60,000 cash bonus. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan. The Restricted Stock vests six months following the grant date. Read SEC document |
| December 14, 2016 Filed Dec 15, 2016 21:33 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 9,165 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-16-000989 · edgar.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,593 F1 · shares: On December 14, 2016, the Company granted 9,165 shares of restricted stock (the "Restricted Stock") to the Reporting Person in satisfaction of previously-deferred base salary. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan. The Restricted Stock vests six months following the grant date. Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 22:11 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 4,069 | $0.32 | $1,302.08 |
DisclosureSEC source: 0000914190-16-000930 · edgar.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,428 Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 21:37 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 6,020 | $0.34 | $2,046.80 |
DisclosureSEC source: 0000914190-16-000921 · edgar.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,359 Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 21:37 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 4,600 | $0.34 | $1,563.54 |
DisclosureSEC source: 0000914190-16-000921 · edgar.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,339 Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 21:28 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 40,599 | $0.32 | $13,016.04 |
DisclosureSEC source: 0000914190-16-000918 · edgar.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,739 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.315 to $0.33 inclusive. The reporting person undertakes to provide Nephros, Inc., any security holder of Nephros, Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 21:28 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 931 | $0.29 | $269.99 |
DisclosureSEC source: 0000914190-16-000918 · edgar.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,140 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.